Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$15.01 - $22.16 $270,360 - $399,145
-18,012 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$21.85 - $30.0 $946,563 - $1.3 Million
-43,321 Reduced 70.63%
18,012 $404,000
Q1 2021

May 17, 2021

BUY
$27.86 - $40.59 $1.71 Million - $2.49 Million
61,333 New
61,333 $1.87 Million

About Aptevo Therapeutics Inc.


  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $24.2M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.